Can a Cure Be Achieved with Taxane-Based Chemotherapy plus Surgery in Patients with Primary Mediastinal Non-Seminomatous Germ Cell Tumors and Progression or Relapse Despite First-Line Chemotherapy?

被引：0

作者：

Miskovska, Vera ^{[1
,2
]}

Levy, Antonin ^{[1
]}

Massard, Christophe C. ^{[1
]}

Gross-Goupil, Marine ^{[1
]}

Bossi, Alberto ^{[1
]}

Fizazi, Karim ^{[1
]}

机构：

[1] Inst Gustave Roussy, Dept Med, Villejuif, France

[2] St Elisabeth Canc Inst, Bratislava, Slovakia

来源：

ONKOLOGIE | 2010年 / 33卷 / 03期

关键词：

mediastinal non-seminomatous germ cell tumor; primary; Taxane; Relapse; CISPLATIN-BASED CHEMOTHERAPY; HIGH-DOSE CHEMOTHERAPY;

D O I：

10.1159/000277824

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Primary mediastinal non-seminomatous germ cell tumors (NSCGTs) have a poor prognosis in the International Germ Cell Cancer Collaborative Group (IGCCCG) classification. There is no clear standard of treatment at relapse. Between 1995 and 2005, 13 patients experienced progression or relapse, and 1 patient was cured with a taxane-based chemotherapy plus surgical resection at our institution.

引用

页码：119 / 120

页数：2

共 38 条

[21] Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer
Auclin, Edouard
Benitez-Montanez, Jose
Tagliamento, Marco
Parisi, Francesca
Gorria, Teresa
Garcia-Campelo, Rosario
Dempsey, Naomi
Pinato, David J.
Reyes, Roxana
Albarran-Artahona, Victor
Dall'Olio, Filippo
Soldato, Davide
Hendriks, Lizza
Nana, Frank Aboubakar
Tonneau, Marion
Lopez-Castro, Rafael
Nadal, Ernest
Kazandjian, Suzanne
Muanza, Thierry
Blanc-Durand, Felix
Fabre, Elizabeth
Castro, Natalia
Arasanz, Hugo
Rochand, Adrien
Besse, Benjamin
Routy, Bertrand
Mezquita, Laura
LUNG CANCER, 2023, 178 : 116 - 122
[22] Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study
Antonelli, Luca
Ardizzone, Davide
Ravi, Praful
Bagrodia, Aditya
Mego, Michal
Daneshmand, Siamak
Nicolai, Nicola
Nazzani, Sebastiano
Giannatempo, Patrizia
Franza, Andrea
Heidenreich, Axel
Paffenholz, Pia
Saoud, Ragheed
Eggener, Scott
Ho, Matthew
Oswald, Nathaniel
Olson, Kathleen
Tryakin, Alexey
Fedyanin, Mikhail
Naoun, Natacha
Javaud, Christophe
Fizazi, Karim
King, Jennifer M.
Adra, Nabil
Douglawi, Antoin
Cary, Clint
Sweeney, Christopher
Fankhauser, Christian D.
EUROPEAN JOURNAL OF CANCER, 2023, 182 : 144 - 154
[23] Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease
Lim, S. H.
Hong, J. Y.
Lim, S. T.
Hong, H.
Arnoud, J.
Zhao, W.
Yoon, D. H.
Tang, T.
Cho, J.
Park, S.
Ko, Y. H.
Kim, S. J.
Suh, C.
Lin, T.
Kim, W. S.
ANNALS OF ONCOLOGY, 2017, 28 (09) : 2199 - 2205
[24] Analysis of ICIs alone or in combination rechallenged outcomes after progression from first-line ICIs plus chemotherapy in patients with advanced non-small cell lung cancer
Yin, Guisen
Liu, Xin
Yu, Xiangtao
Tan, Song
Liu, Fen
SCIENTIFIC REPORTS, 2025, 15 (01):
[25] CT-based radiomics signatures can predict the tumor response of non-small cell lung cancer patients treated with first-line chemotherapy and targeted therapy
Fengchang Yang
Jiayi Zhang
Liu Zhou
Wei Xia
Rui Zhang
Haifeng Wei
Jinxue Feng
Xingyu Zhao
Junming Jian
Xin Gao
Shuanghu Yuan
European Radiology, 2022, 32 : 1538 - 1547
[26] CT-based radiomics signatures can predict the tumor response of non-small cell lung cancer patients treated with first-line chemotherapy and targeted therapy
Yang, Fengchang
Zhang, Jiayi
Zhou, Liu
Xia, Wei
Zhang, Rui
Wei, Haifeng
Feng, Jinxue
Zhao, Xingyu
Jian, Junming
Gao, Xin
Yuan, Shuanghu
EUROPEAN RADIOLOGY, 2022, 32 (03) : 1538 - 1547
[27] Association between Expression of ERCC1, XPA and 8092C>A of ERCC1, 5'UTR of XPA Polymorphisms and Clinical Response to Cisplatin-Based Chemotherapy and Survival in Patients with Non-Seminomatous Testicular Germ Cell Tumors.
Mendoza, J.
Hernandez, C.
Martinez, J.
Perez-Montiel, D.
Castro, C.
Fabian-Morales, E.
Santibanez, M.
Gonzalez-Barrios, R.
Soto-Reyes, E.
Diaz-Chavez, J.
Onate, L.
Jimenez, M.
Nunez, M.
Dyer, R.
Herrera, L. A.
MOLECULAR BIOLOGY OF THE CELL, 2012, 23
[28] Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non-small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy
Vansteenkiste, Johan
Lara, Primo N., Jr.
Le Chevalier, Thierry
Breton, Jean-Luc
Bonomi, Philip
Sandler, Alan B.
Socinski, Mark A.
Delbaldo, Catherine
McHenry, Brent
Lebwohl, David
Peck, Ronald
Edelman, Mark
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (23) : 3448 - 3455
[29] Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02-15 study)
Auliac, Jean-Bernard
Monnet, Isabelle
Bizieux, Acya
Greillier, Laurent
Geier, Margaux
Falchero, Lionel
Le Garff, Gwenaelle
Lamy, Regine
Guisier, Florian
Ricordel, Charles
Chouaid, Christos
Vergnenegre, Alain
LUNG CANCER, 2021, 161 : 122 - 127
[30] Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non-small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy (vol 25, pg 3448, 2007)
Vansteenkiste
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5339 - 5339

← 1 2 3 4 →